Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Laser-assisted sYnthesis of Magnetically mOtile plasmonic chiral Nanocatalysts

Project description

Reusable magnetic chiroplasmonic nanocatalysts for anticancer drugs

Catalysis is crucial for sustainable chemical manufacturing and the production of affordable, life-saving drugs. However, challenges arise in anticancer drug synthesis due to the asymmetric nature of biological processes. Chiral plasmonic nanoparticles (NPs) show promise with their unique optical properties. Integrating magnetic properties into these NPs could facilitate easy removal and recycling, thus reducing chemical waste. However, this combination remains unexplored. With support from the Marie Skłodowska-Curie Actions programme, the LYMON project will improve chiral nanocatalyst construction using a laser-based method. This will create reusable magnetic chiroplasmonic nanocatalysts, reducing side reactions and enhancing control over pharmaceutical production, particularly for anticancer drugs. It will also advance synthetic chemistry and enable the production of selective molecules.

Objective

Catalysis holds immense significance in chemical manufacturing, being a key player in developing sustainable industrial processes with limited energy & resource consumption. In pharmaceutical industry, catalysis is crucial for enabling mass production of affordable life-saving drugs. However, developing efficient catalysts for this sector poses a formidable challenge due to the inherent asymmetry of many biological processes. This is particularly critical in producing anticancer drugs because their synthesis relies on intermediates or reactions whose asymmetric nature, known as chirality, withholds their massive production, limiting equal global access to best health treatments.
An up-and-coming solution to address this dilemma is resorting to chiral plasmonic nanoparticles (NPs), as their outstanding optical rotation activity makes them well-suited for applications like polarization-sensitive photocatalysis, especially in the context of anticancer drug development. However, unleashing its full potential hinges on imbuing these chiral NPs with unusual properties like magnetism, allowing safe removal from products & recyclability without generating chemical waste. To date, creating a plasmonic structure that seamlessly integrates chirality with magnetic motility remains largely underexplored.
The LYMON project addresses this conundrum by expanding the repertoire of chiral nanocatalyst construction methods through a groundbreaking laser-based pathway. This innovative approach, supported both experimentally & theoretically, promises to bring a new generation of highly specific magnetic chiroplasmonic nanocatalysts characterized by their ability to be reused multiple times. All of this permiting reducing wasteful side reactions & improving control over pharmaceutical production, especially for anticancer drugs. Moreover, it promises to expand the horizons of synthetic chemistry, paving the way for cutting-edge routes to produce highly efficient & selective molecules.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

UNIVERSITA DEGLI STUDI DI PADOVA
Net EU contribution
€ 188 590,08
Address
VIA 8 FEBBRAIO 2
35122 Padova
Italy
Region
Nord-Est Veneto Padova
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)